Avalyn Pharma Prices Upsized IPO at $18 a Share, Targeting $300 Million in Gross Proceeds
Avalyn Pharma Inc. has priced an upsized initial public offering of 16,666,667 shares at $18.00 per share, for expected gross proceeds of $300 million. The company granted underwriters a 30-day option to purchase an additional 2,500,000 shares. Shares are slated to begin trading on the Nasdaq Global Select Market on April 30, 2026 under the ticker …